EA201290036A1 - Липидированные производные оксоаденина - Google Patents

Липидированные производные оксоаденина

Info

Publication number
EA201290036A1
EA201290036A1 EA201290036A EA201290036A EA201290036A1 EA 201290036 A1 EA201290036 A1 EA 201290036A1 EA 201290036 A EA201290036 A EA 201290036A EA 201290036 A EA201290036 A EA 201290036A EA 201290036 A1 EA201290036 A1 EA 201290036A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lipidated
oxoadenine
derivatives
oxoadenine derivatives
oxoadenines
Prior art date
Application number
EA201290036A
Other languages
English (en)
Other versions
EA023536B1 (ru
Inventor
Дэвид Джонсон
Original Assignee
Глаксосмитклайн Байолоджикалс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс Са filed Critical Глаксосмитклайн Байолоджикалс Са
Publication of EA201290036A1 publication Critical patent/EA201290036A1/ru
Publication of EA023536B1 publication Critical patent/EA023536B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Новые липидированные оксоаденины, содержащие замещенную азотсодержащим гетероциклилом молекулу оксоаденина, ковалентно связанную с фосфо- или фосфонолипидом, являются, как показано, индукторами интерферона-α и других иммуностимулирующих цитокинов. Соединения полезны в качестве иммуностимуляторов и адъювантов.
EA201290036A 2009-08-07 2010-08-06 Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами EA023536B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23213209P 2009-08-07 2009-08-07
PCT/US2010/044703 WO2011017611A1 (en) 2009-08-07 2010-08-06 Lipidated oxoadenine derivatives

Publications (2)

Publication Number Publication Date
EA201290036A1 true EA201290036A1 (ru) 2012-12-28
EA023536B1 EA023536B1 (ru) 2016-06-30

Family

ID=43544685

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290036A EA023536B1 (ru) 2009-08-07 2010-08-06 Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами

Country Status (15)

Country Link
US (1) US9044481B2 (ru)
EP (2) EP2461690A4 (ru)
JP (1) JP5759992B2 (ru)
KR (1) KR20120055623A (ru)
CN (1) CN102469790B (ru)
AU (1) AU2010279299B2 (ru)
BR (1) BR112012002349A2 (ru)
CA (1) CA2768195A1 (ru)
EA (1) EA023536B1 (ru)
ES (1) ES2732999T3 (ru)
MX (1) MX2012001524A (ru)
SG (1) SG178237A1 (ru)
TR (1) TR201909600T4 (ru)
WO (1) WO2011017611A1 (ru)
ZA (1) ZA201200646B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
SG193149A1 (en) * 2008-08-11 2013-09-30 Glaxosmithkline Llc Novel adenine derivatives
EP2324025A1 (en) * 2008-08-11 2011-05-25 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (ru) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Производные пурина для применения в лечении аллергий, воспалительных и инфекционных заболеваний
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
NO2491035T3 (ru) 2009-10-22 2018-01-27
JP2013519644A (ja) 2010-02-10 2013-05-30 グラクソスミスクライン エルエルシー プリン誘導体およびそれらの薬学的使用
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
AU2011247359A1 (en) * 2010-04-30 2012-11-15 Telormedix Sa Methods for inducing an immune response
US10112946B2 (en) 2011-07-22 2018-10-30 Glaxosmithkline Llc Composition
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
US9555036B2 (en) 2012-08-24 2017-01-31 Glaxosmithkline Llc Pyrazolopyrimidine compounds
PT2922549T (pt) * 2012-11-20 2017-09-01 Glaxosmithkline Llc Novos compostos
WO2014081644A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
ES2625023T3 (es) 2012-11-20 2017-07-18 Glaxosmithkline Llc Compuestos novedosos
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
WO2015036044A1 (en) * 2013-09-13 2015-03-19 Telormedix Sa Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood
AR100137A1 (es) 2014-04-22 2016-09-14 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
LT3265458T (lt) 2015-03-06 2019-03-12 F. Hoffmann-La Roche Ag Benzazepino dikarboksamido junginiai
WO2016142880A1 (en) * 2015-03-10 2016-09-15 Glaxosmithkline Biologicals Sa Compositions and uses
EP3350168B1 (en) 2015-09-17 2019-12-18 H. Hoffnabb-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
EP3355933B1 (en) 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
US10632192B2 (en) 2015-10-07 2020-04-28 Sumitomo Dainippon Pharma Co., Ltd. Pyrimidine compounds and their use as vaccine adjuvants
US10774099B2 (en) 2015-12-14 2020-09-15 Glaxosmithkline Biologicals Sa Phospholipidation of imidazoquinolines and oxoadenines
JP6918838B2 (ja) 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP7022702B2 (ja) 2016-05-23 2022-02-18 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
EP3774806A1 (en) 2018-04-13 2021-02-17 GlaxoSmithKline Biologicals SA Tlr7 and / or tlr8 agonists
BR112020026890A2 (pt) 2018-07-03 2021-03-30 Jiangsu Hengrui Medicine Co., Ltd. Derivado de piridopirimidina, método de preparação do mesmo e uso médico do mesmo
US20210353737A1 (en) 2018-07-23 2021-11-18 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
KR20220018503A (ko) * 2019-05-23 2022-02-15 더 유니버시티 오브 몬타나 Tlr 수용체 리간드에 기반한 백신 애주번트
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
AU2020416484A1 (en) 2020-01-02 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of pyridopyrimidine derivative and preparation method thereof
KR102549083B1 (ko) 2021-02-01 2023-06-29 주식회사 에이티솔루션 레이다 전자 표적 발생 장치에서 발생되는 표적의 거리를 최소화하는 전파 지연 장치 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3042540B2 (ja) * 1990-08-20 2000-05-15 ミヨシ油脂株式会社 8―ヒドロキシアデノシン―5′―リン酸を含むアデノシンモノホスフェート系三量体、その製造方法及びその化合物からなる蛋白質合成阻害剤
JPH093091A (ja) * 1995-06-21 1997-01-07 Rikagaku Kenkyusho ヌクレオシド誘導体物質、その製造法及び抗腫瘍剤
ES2232871T3 (es) * 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
WO2003066649A1 (en) * 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
ES2437871T3 (es) * 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
DK2132209T3 (da) * 2007-03-19 2014-04-14 Astrazeneca Ab 9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7)
JP5519670B2 (ja) * 2008-08-11 2014-06-11 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
EP2324025A1 (en) * 2008-08-11 2011-05-25 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases

Also Published As

Publication number Publication date
BR112012002349A2 (pt) 2015-10-13
EP2461690A4 (en) 2013-03-27
KR20120055623A (ko) 2012-05-31
EA023536B1 (ru) 2016-06-30
AU2010279299A1 (en) 2012-03-29
EP3199159B1 (en) 2019-04-10
CN102469790A (zh) 2012-05-23
AU2010279299B2 (en) 2015-10-01
WO2011017611A1 (en) 2011-02-10
TR201909600T4 (tr) 2019-07-22
JP2013501730A (ja) 2013-01-17
EP3199159A1 (en) 2017-08-02
SG178237A1 (en) 2012-03-29
JP5759992B2 (ja) 2015-08-05
US9044481B2 (en) 2015-06-02
ZA201200646B (en) 2013-06-26
ES2732999T3 (es) 2019-11-27
US20120135963A1 (en) 2012-05-31
CA2768195A1 (en) 2011-02-10
MX2012001524A (es) 2012-02-29
CN102469790B (zh) 2014-12-03
EP2461690A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
EA201290036A1 (ru) Липидированные производные оксоаденина
CY1118199T1 (el) Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201590534A1 (ru) Новые бициклические производные
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
DK1791571T3 (da) Radiofluorinerede peptider
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
MX2014010551A (es) N-ciclilamidas como nematicidas.
EA201100268A1 (ru) Вакцина
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
JP2014526140A5 (ru)
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
FR2963728B1 (fr) Table pliante, portable, en particulier table de massage.
EA201290642A1 (ru) Соединения и способы
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
EA201390799A1 (ru) Триазолопиридины
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
CY1117912T1 (el) Ενωσεις πυραζολιου ως αναστολεiς του συμμεταφορεα νατριου-γλυκοζης 1 (sglt1)
TN2011000355A1 (en) Novel microbiocides
MX348786B (es) Agentes osmoticos de polisacarido esterificado.
EA201290243A1 (ru) Хиназолиновые соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU